Form 4: CEO Sells SOPHiA GENETICS Shares Under 10b5-1 Plan

Jurgi Camblong, CEO of SOPHiA GENETICS SA, reported the sale of 5,100 ordinary shares through two transactions executed on April 6 and 7, 2026, under a pre-established Rule 10b5-1 trading plan.

Summary

• Jurgi Camblong, CEO and Director of SOPHiA GENETICS SA, sold a total of 5,100 ordinary shares.
• The sales occurred on April 6, 2026 (2,600 shares) and April 7, 2026 (2,500 shares).
• These transactions were conducted under a Rule 10b5-1 trading plan, designed to satisfy affirmative defense conditions for insider trading.
• The sales were made to satisfy tax withholding obligations related to the vesting of restricted stock units on April 2 and 3, 2026.
• The weighted average sale price on April 6 was $4.8517, with individual sales ranging from $4.71 to $4.95.
• The weighted average sale price on April 7 was $4.8619, with individual sales ranging from $4.69 to $4.98.
• Following these transactions, Camblong beneficially owns 3,728,950 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the clear explanation of tax obligations and the use of a Rule 10b5-1 plan mitigate significant concern.

Positives

• The sales were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less concerning insider selling.
• The sales were to cover tax obligations, a common and often necessary reason for executives to sell shares.
• The reporting person retains a significant number of shares (3,728,950) after the transactions.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.
• The sales represent a small portion of the CEO's holdings, but any reduction in ownership by a top executive warrants attention.

Risks

• The filing does not explicitly mention any new risks. The sales are attributed to tax obligations and a pre-arranged trading plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• Sales were made to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by SOPHiA GENETICS SA's CEO is a common practice to manage potential conflicts with insider trading regulations when executives need to sell shares for personal financial planning, such as covering tax liabilities.

Stakeholder Impact

• Shareholders: May interpret insider selling, even under a 10b5-1 plan, as a slight negative signal, though the reasons provided are standard.
• Employees: The vesting of RSUs and subsequent tax withholding sales by the CEO are routine events.
• Management: The CEO is managing personal financial obligations in compliance with regulatory requirements.

Next Steps

• Monitor future Form 4 filings for any additional transactions by Jurgi Camblong or other insiders.
• Observe the company's stock performance and any subsequent disclosures for further context.

Key Dates

Recommendation

This Form 4 filing reports routine insider sales to cover tax obligations under a pre-established 10b5-1 plan. While insider selling can be a concern, the structured nature of these sales and the stated purpose suggest it is not indicative of a negative view on the company's future prospects. Therefore, a 'hold' recommendation is appropriate, pending further company-specific news or financial performance updates.

Keywords

SOPHiA GENETICS SA, SOPH, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, CEO, Jurgi Camblong, Beneficial Ownership, Restricted Stock Units, Tax Withholding